Affiliation:
1. Graduate Field of Biophysics Cornell University Ithaca NY 14853 USA
2. Robert Frederick Smith School of Chemical and Biomolecular Engineering Cornell University Ithaca NY 14853 USA
3. Nancy E. and Peter C. Meinig School of Biomedical Engineering Cornell University Ithaca NY 14853 USA
4. Department of Materials Science and Engineering Cornell University Ithaca NY 14853 USA
5. Kavli Institute at Cornell for Nanoscale Science Cornell University Ithaca NY 14853 USA
Abstract
AbstractSkeletal metastasis is common in patients with advanced breast cancer and often caused by immune evasion of disseminated tumor cells (DTCs). In the skeleton, tumor cells not only disseminate to the bone marrow but also to osteogenic niches in which they interact with newly mineralizing bone extracellular matrix (ECM). However, it remains unclear how mineralization of collagen type I, the primary component of bone ECM, regulates tumor‐immune cell interactions. Here, a combination of synthetic bone matrix models with controlled mineral content, nanoscale optical imaging, and flow cytometry are utilized to evaluate how collagen type I mineralization affects the biochemical and biophysical properties of the tumor cell glycocalyx, a dense layer of glycosylated proteins and lipids decorating their cell surface. These results suggest that collagen mineralization upregulates mucin‐type O‐glycosylation and sialylation by tumor cells, which increases their glycocalyx thickness while enhancing resistance to attack by natural killer (NK) cells. These changes are functionally linked as treatment with a sialylation inhibitor decreased mineralization‐dependent glycocalyx thickness and made tumor cells more susceptible to NK cell attack. Together, these results suggest that interference with glycocalyx sialylation may represent a therapeutic strategy to enhance cancer immunotherapies targeting bone‐metastatic breast cancer.
Funder
National Institutes of Health
National Science Foundation
New York State Stem Cell Science